OncLive TV

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Noopur S. Raje, MD, discusses recent findings with melflufen in relapsed/refractory multiple myeloma.

Kamran A. Ahmed, MD, discusses remaining questions with the use of tucatinib in breast cancer–related brain metastases.

Muhammad Bilal Abid, MD, MRCP, discusses challenges with CAR-T cell therapy during the coronavirus disease 2019 pandemic.

Luciano J. Costa, MD, PhD, discusses unmet need​s in relapsed/refractory multiple myeloma. 

Gary K. Schwartz, MD, discusses the results from the gastrointestinal stromal tumor cohort of the phase 2 Alliance A091401 trial.

Brian Czerniecki, MD, PhD, discusses the benefit of tucatinib in patients with HER2-positive breast cancer and brain metastases.

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule hypoxia-inducible factor-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

John O. Mascarenhas, MD, discusses approved and emerging treatment options in myelofibrosis.

Sagar Lonial, MD, FACP, discusses the FDA approval of belantamab mafodotin in patients with relapsed/refractory multiple myeloma.

Christina L. Roland, MD, MS, FACS, discusses the safety profile of neoadjuvant checkpoint blockade in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Christian U. Blank, MD, PhD, discusses the future of baseline biomarkers in macroscopic stage 3 melanoma.

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Noopur S. Raje, MD, discusses remaining questions in multiple myeloma. 

Michael Wang, MD, discusses the importance of additional CAR T-cell therapy research in mantle cell lymphoma.

Ruben A. Mesa, MD, discusses mitigating racial disparities in myeloproliferative neoplasm clinical trials.

Kami J. Maddocks, MD, discusses treatment considerations for treatment selection in follicular lymphoma.

Andrei Gafita, MD, discusses key takeaways from a retrospective analysis evaluating lutetium-177 PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Monica Balzarotti, MD, discusses remaining questions regarding consolidation and maintenance therapy in relapsed/refractory diffuse large B-cell lymphoma.

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

Shannon N. Westin, MD, MPH, discusses challenges with precision medicine in endometrial cancer. 

Neal D. Shore, MD, FACS, discusses challenges with androgen deprivation therapy in recurrent prostate cancer.

Othman Al-Sawaf, MD, discusses new safety signals with venetoclax plus obinutuzumab in the phase 3 CLL14 trial.

Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.

Shaji K. Kumar, MD, discusses treatment discontinuation in the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Hatem Soliman, MD, discusses the rationale for using immunotherapy in triple-negative breast cancer.

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Michael Wang, MD, discusses the safety profile of ​the CAR T-cell therapy brexucabtagene autoleucel in ​relapsed/refractory mantle cell lymphoma.

Mansoor Raza Mirza, MD, discusses the final survival analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trial in recurrent, platinum-sensitive ovarian cancer.